updat forecast estim sep
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research aug
estim sep
price data sep
rate updat sep
currenc amount express
busi strategi outlook
methodolog valu compani
busi strategi outlook
stand largest pure-play medic devic
maker remain forc reckon med-tech
wide rang chronic diseas legaci covidien breadth
product acut care hospit bolster
posit key partner hospit custom
histor focus innov design
manufactur devic address cardiac care neurolog
spinal condit diabet along firm remain
focus fundament strategi innov often first
market new product invest heavili intern
research develop effort well acquir emerg
technolog howev postreform healthcar world
higher hurdl secur reimburs
next-gener technolog slightli shift
strategi focu partner close hospit client
offer greater breadth product servic help
hospit oper effici partner close
integr hospit oper well
posit take advantag busi opportun
value-bas reimburs environ view particular
pioneer risk-bas contract around
cardiac diabet product think
attract hospit client payer alik
alway appreci divers portfolio
certain wane product line would off-set growth
categori addit devic consum use
surgic suit stabil potenti speed bump
individu product line continu focu
gener roughli billion chines sale fiscal
broad portfolio product fit well
firm earlier purchas kanghui hold provid
firm establish network nativ distributor
reach thousand hospit china
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
one largest medic devic compani develop
manufactur therapeut medic devic chronic diseas portfolio
spinal fixat devic neurovascular product surgic tool
compani market product healthcar institut physician
unit state oversea foreign sale account
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
gener met expect top line
slightli exceed bottom-lin estim firm
tighten expens control howev dont anticip
materi chang fair valu estim
increment adjust think share
fairli valu remain confid wide
econom moat firm continu introduc product
improv new
medtron breadth signific presenc key
therapeut area allow firm catch instanc
fallen behind technolog front
impress strong growth brain
therapi minim invas therapi coronari
structur heart unit featur key product
deliv double-digit growth includ stent retriev
corevalv transcathet aortic valv replac
expect product line remain growth mode
product adopt indic expans fuel demand
exampl new low-risk indic corevalv coupl
recent nation coverag determin
medicar bolster steadi demand
diabet divis saw challeng condit
explos growth unit state slow
off-set strong demand outsid
nonetheless remain fan competit
posit market launch next-gener
expect later fiscal year along two new
continu glucos monitor sensor time
medtron synergi sensor demonstr
difficult beat firm even competitor enjoy
head start though medtron long lag
cgm technolog gap quickli close
sensor significantli reduc need finger stick
calibr devic -- key complaint medtron
current sensor synergi sensor one-piec unit
combin transmitt final
made strateg decis work new insulin pump
offer
interoper diabet
compon devic cgm
signific step histor lock
patient proprietari devic system
howev think retain competit
advantag even interoper thank enorm
studi relationship payer
hold steadi fair valu estim
continu incorpor fairli optimist expect
structur heart diabet
neurovascular unit well
expans follow sale legaci covidien medic
suppli busi
shed busi project
averag annual top-lin growth remain
product line howev expect new
neuromodul indic drug-elut balloon
insulin pump on-going develop atrial fibril
market transcathet valv sale defend
price eros near term estim slightli faster
averag annual revenu growth restor
therapi group fiscal driven adopt
new technolog neuromodul neurovascular
return growth spine busi thank
addit mazor robot
legaci gross margin histor
held firm addit covidien lower
roughli basi point firm made
gradual steadi progress rais gross margin
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
pull-through emerg new partnership
outsourc agreement forg
hospit client firm new product surpris us
upsid increment product revenu associ
servic agreement exceed expect firm
lower manufactur cost wring
administr save expect next
year fair valu estim would rise per share
hand cardiovascular divis remain
mire low-single-digit growth price pressur
corevalv increas intrepid mitral valv fail
mazor robot abl return spine growth product
pull-through emerg fair valu estim
would fall per share
wide moat root domin presenc
highli engin medic devic treat chronic
diseas includ beyond histor stronghold
heart diseas moat come sever
cardiac area compet roughli three
competitor total across heart-rel portfolio
market pacemak icd coronari stent heart valv
neuromodul gener oper
oligopoli switch cost relat
cardiac rhythm manag devic transcathet
spine area moat strengthen high
switch cost surgeon doctor often reli medic
devic sale rep deep devic knowledg well
experi devic usag wide rang
patient result rep play role highli
special expert advis practition
implant program mainten medtron
devic creat sticki relationship medic
basi point last four year think
compani eke increment improv
next year ration manufactur
asset project normal gross margin
longer term expect cost synergi
emerg sale administr thank
cross-sel bundl product servic
base averag volatil cash flow divers
product portfolio rel less discretionari therapeut
market rate uncertainti medium
atrial
base case assum see
low-single-digit growth busi penetr
risk-bas tyrx contract program grow
complement
endovascular structur heart surgic technolog
expect spinal devic infus regain
double-digit growth seen howev biggest
wild card quickli introduc
meaning innov support favor
clinic evid magnitud product
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
practition dynam tend keep spinal surgeon
loyal product long compani
fall far behind competitor come
final wide moat bolster sever
intang includ intellectu properti care
nurtur relationship physician thank
persist abil innov often first
market new product variou therapeut area
expect continu record innov base
extens patent portfolio accord independ
patent board hold strongest
intellectu properti posit base number
technolog strength patent
portfolio allow better weather occasion glitch
develop approv process particular new
devic invest neuromodul diabet
spinal product middl late paid
spade although spine
busi hit slower market growth sinc
firm seen double-digit growth diabet
atrial fibril segment
product line wane new clinic data alter
treatment guidelin firm continu invest
emerg technolog includ renal denerv
transcathet mitral valv drive futur growth
addit covidien deepen competit
advantag covidien medic devic segment enjoy
brand recognit technolog innov substanti
record enhanc
increment research invest past year
result steadi stream product upgrad
new technolog covidien devic subseg
oper oligopolist fashion absenc irrat
price competit evolutionari
rather
revolutionari natur innov tend lead
margin share shift industri strong excess
return covidien current rank near top
product categori compet devic vie
mainli johnson johnson rest field
fragment compani
occupi product nich rather compet broadli
big two
seen new entrant make signific inroad
new competitor sometim pop margin rang
less sophist discount price high-end
technolog advanc rare result
defens practition rare switch
competitor product inertia well
up-front train cost surgeon influenc
procur decis arguabl wane establish
player also administr ear covidien
domin number surgic specialti breadth
portfolio render competitor effort displac
cost individu product basi less meaning
moat remain stabl partli thank stabl
oligopoli compet primarili
abbott purchas st jude medic edward
lifesci cardiac devic johnson
johnson hospital-ori surgic devic tool
competitor may trade market share point
sever year rel short product cycl allow
peer regain share fairli quickli
consist control cardiac rhythm
manag market also domin competitor
structur heart neuromodul insulin pump
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
firm continu innov intern well purchas
new complementari technolog remain
forefront medic devic
wake healthcar reform doctor sign
employe healthcar provid think shift
realign doctor financi interest
hospit practic group howev alreadi
maneuv better posit partner
hospit healthcar system doctor see
influenc wane wide-rang product portfolio
particularli suit play role way
competitor introduc servic
wrap around devic
new hospit solut servic taken
big step new role manag catheter
electrophysiolog lab deliv oper
effici think hospit could seek firm
servic turn closer integr
servic hospit oper could also rais
switch cost hospit custom
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
histor held roughli share
core heart devic also market leader
spinal product insulin pump neuromodul
chronic pain
pipelin contain treatment atrial
fibril mitral valv diseas
denerv hypertens new therapi
prove effect could domin three
often find novel way appli familiar
technolog like use implant electron
pacemak
incontin chronic pain
address
technolog may face stiffer fight
maintain leadership arena
devic indirectli subject medicar
increas pressur
oover year issu number
voluntari recal product although
fatal associ problem
effort hurt doctor confid
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
financi health deterior somewhat
financ signific portion covidien merger
new debt issuanc covidien sharehold own
combin entiti time merger
allow combin entiti invert covidien irish
domicil lower tax rate enhanc abil
access oversea cash end januari
owe billion debt around time
adjust ebitda around time
histor sinc firm paid roughli
billion debt think medtron easili shoulder
current debt load beyond debt oblig firm
aim return minimum annual free cash
flow sharehold shoot dividend
pay-out ratio consist engag share repurchas
base averag volatil cash flow divers
product portfolio rel less discretionari therapeut
market rate uncertainti medium
babi boomer hit medicar age could futur
cut medicar reimburs device-rel
procedur would translat financi pressur
hospit custom innov name
game medic devic bar rais
wake healthcar reform success secur price
premium new technolog longer given
depend favor clinic data increas regulatori
attent interest conduct extens clinic
trial aftermarket studi could increas develop
cost product recal liabil
inventori write-down occasion sore spot
industri although depart justic wrap
investig off-label use infus product
without issu charg controversi around
investig ad uncertainti contribut declin
infus sale potenti investig product
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
market remain risk medic devic
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
ceo/ceo subsidiary/chairman
board/chairman board
repres date owner name posit common share held report holder issuer
new york mellon corp
capit research manag compani
share
fund
share
fund
omar ishrak left lead
ceo chairman littl direct experi
cardiac market devic industri
consid rise star ge ishrak pioneer behind
ge healthcar success entranc china
market -- led effort expand product portfolio
order compet head head local chines imag
compani mindray gave ge substanti
leg midmarket china consid
make number invest
china india identifi emerg market
strateg sourc growth think ishrak bring valuabl
perspect parti think success
push away -centric past
focus organ close potenti
emerg market led firm invest new area
technolog renal denerv spine robot
importantli drive forc behind
effort posit new product servic help
hospit custom improv outcom lower cost -- key
prioriti shift hospit purchas behavior
wake afford act
think addit former sell-sid analyst mike
weinstein lead corpor strategi intrigu
move believ weinstein bring deep
well med-tech expertis connect industri
cfo karen parkhil lack came bank
background expect weinstein sharpen
medtron focu activ help streamlin
portfolio includ potenti sale product
busi influenc clarifi firm approach
capit alloc
decis primarili solid occasion
misstep come acquisit like major
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
acquisit smaller often privat held firm offer
emerg technolog purchas typic dilut
short term technolog still requir much
develop reach commerci though
difficult assess valu purchas
tend view invest akin intern
invest must make main
concern even though seen
pattern goodwil impair past
hesit poni gener offer certain acquisit
target seem add valu longer term
exampl spent billion purchas
kyphon acquisit turn
disappoint
synergi term sale market physician
relationship abl goos
kyphon product back robust growth howev
think mani acquisit add
valu time includ mazor covidien ardian
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
chang fve may
post strong fiscal fourth-quart result
larg met full-year top-lin expect nearli
hit expens project nose expect leav
fair valu unchang roll model make
slight near-term adjust project
revenu growth cardiovascular group fell slightli short
expect off-set stronger-than-
expect growth minim
invas
restor therapi group remain confid
firm wide econom moat support continu
adopt innov product steadi stream new
product pipelin across therapeut area
though spine busi character
slow declin decad weve long
pessimist market gener think
addit mazor robot could chang script spur
sustain growth spine unit similar
stryker strategi mako robot hip knee
replac acquisit mazor provid
market-lead footprint emerg area spine
robot think robot contribut spine product
pull-through afford opportun shift practition
higher-margin consum discuss
past joint replac robot current
difficult assess whether spinal robot lead better
patient outcom take year collect clinic data
nonetheless knee replac sizabl
group patient dissatisfi outcom
think contribut appetit among spine
surgeon tri technolog adopt also
bolster secular shift open surgeri
minim invas spine procedur like
benefit real-tim imag precis
effect one way
found issu quarter intrigu
first favor registri data medtron symplic renal
denerv procedur hypertens share last
month three year procedur decreas
systol blood pressur number top
sustain bode well pivot trial current
underway expect see initi data next spring
remain renal denerv lead
think uncontrol hypertens market could
second continu think risk-bas
contract tyrx antibacteri envelop help
insul firm competit although fiscal
fourth-quart declin cardiac rhythm
manag heart failur disappoint
contrast domest declin abbott
saw busi last quarter point appear
gain share abbott
bear brunt loss less
third track implant first in-human
transsept deliveri end year firm
alreadi well pivot apollo trial transap
deliveri enter rib upward
left ventricl firm ahead competitor
time standpoint consensu among research
thought leader intervent cardiolog
shift toward transsept deliveri base lower
level success outcom weve seen transap
transcathet aortic valv replac consid
bulkier stent-in-st design intrepid tmv product
weve temper expect well
product re-engin transsept deliveri
requir number tight turn navig left
atrium reach mitral valv detail
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
analysi transcathet mitral valv technolog pleas
see matter heart revisit transcathet mitral
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
financi summari forecast
fiscal year end april
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
fiscal year end april
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
